407 related articles for article (PubMed ID: 31673875)
1. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
[TBL] [Abstract][Full Text] [Related]
3. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
Gardin A; Ufer M; Legangneux E; Rossato G; Jin Y; Su Z; Pal P; Li W; Shakeri-Nejad K
Clin Pharmacokinet; 2019 Mar; 58(3):349-361. PubMed ID: 30088221
[TBL] [Abstract][Full Text] [Related]
7. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
8. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
9. Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants.
Jaiprasart P; Hellemans P; Jiao JJ; Dosne AG; De Meulder M; De Zwart L; Brees L; Zhu W
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38740493
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
11. Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
Gardin A; Shakeri-Nejad K; Feller A; Huth F; Neelakantham S; Dumitras S
Eur J Clin Pharmacol; 2019 Nov; 75(11):1565-1574. PubMed ID: 31392364
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
[TBL] [Abstract][Full Text] [Related]
18. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects.
Aslanis V; Umehara K; Huth F; Ouatas T; Bharathy S; Butler AA; Zhou W; Gadbaw B
Cancer Chemother Pharmacol; 2019 Oct; 84(4):749-757. PubMed ID: 31324935
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Y; Ogasawara K; Wood-Horrall R; Thomas M; Thomas M; He B; Liu L; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2022 Oct; 90(4):325-334. PubMed ID: 36001108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]